Aurora BioPharma to Present at the 2016 Aegis Growth Conference
CAMBRIDGE, MA - September 16, 2016 - Aurora BioPharma, Inc., CEO, Robert Brooks, will present at the 2016 Aegis Growth Conference taking place at the Encore at Wynn Las Vegas September 20 - 22.
About Aurora BioPharma
Aurora BioPharma is a biotechnology company, revolutionizing the way we will treat cancer in the future. After 50 years of surgery, radiation and chemotherapy, cancer rates are still expected to double in the next 15 years. Medicine has a new weapon, genetically reprogramming the immune system into an elite killer army. Already three companies involved in genetically engineered Chimeric Antigen Receptor (CAR) T therapy, have been awarded Breakthrough Therapy Designation by the FDA for showing up to 90% remissions or nearly a "cure" in leukemia and other liquid tumors. Aurora has shown in a human Phase I/II trial with Glioblastoma, the most lethal brain cancer, nearly double the survival of a $1 Billion drug without the side effects. Glioblastoma claimed the lives of Senator Ted Kennedy and Vice President Biden's son, and many others.
About Aegis Capital Corp.
Founded in 1984, Aegis Capital Corp. is a full service retail and institutional broker-dealer located in New York City. Our management is committed to providing the highest level of service to our clients. Our continuous investment in technology provides our customers with access to third-party custody and clearing services through RBC's multiple execution platforms, access to all major exchanges, relationships with floor brokers, access to all electronic market centers (including arca), an institutional trading desk, a fixed income desk to access corporate, government and municipal issues, and market-making services. We provide access to independent research for our financial advisors and their clients from Bloomberg, Moody's, Lipper, Best Independent Research LLC, and Argus Research.
For media inquiries, please contact:
Tel: (617) 674-7718 - Fax: (617) 674-7701
SOURCE Aurora BioPharma, Inc.